Melanoma – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Melanoma arises from the melanocytes of cutaneous or other pigmented tissues such as the eyes or intestines. About 90% of melanomas are diagnosed as primary tumors without any evidence of metastasis. Melanoma when malignant has a marked propensity to metastasize to the brain. Australia has the highest melanoma incidence rate, New Zealand has the highest melanoma mortality rate. The major oncogenic mutations associated with melanoma are BRAF, NRAS, c-KIT, PTEN, and GNAQ/GNA11. BRAF is the most widely studied mutation; prevalence in primary melanoma ranges from 50% to 60%. Around 5% to 12% of the patients with melanoma have a family history of CMM in one or more first-degree relatives.

·       So far, more than 75 somatic mutations in the BRAF gene have been identified in melanoma, and all mutations at V600 in exon 15 constitutively activate BRAF.

·       The mutations are either in the activating segment in exon 15 or the glycine-rich loop (P-loop) in exon 11 of the kinase domain of the BRAF protein. In BRAF mutant melanoma, 74% to 90% are V600E and 16% to 29% are V600K mutations. The frequency of BRAF mutation in primary melanomas ranges from 50% to 60%.

 

The competitive landscape of Melanoma includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Melanoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Melanoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Melanoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          mRNA-4157      ModernaTX, Inc.           Phase 2

2          Ipilimumab        Idera Pharmaceuticals, Inc.        Phase 3

3          CMP-001          Checkmate Pharmaceuticals      Phase 3

4          BNT111            BioNTech SE    Phase 2

5          HX008  Taizhou Hanzhong biomedical co. LTD   Phase 2

6          TIL-168 Instil Bio            Phase 2

7          APX005M         Apexigen, Inc.   Phase 2

8          AU-011 Aura Biosciences           Phase 2

9          Pembrolizumab Merck Sharp & Dohme Corp.     Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more